Axsome First Quarter Financial Results

Axsome Therapeutics released impressive first quarter results this morning. The biggest positive was that four Alzheimer's Agitation clinical trials are to complete, which will lead to a NDA (new drug application) for that indication. Two clinical trials ADVANCE 1 and 2, have been designed as parallel assignment,  and two clinical trials ACCORD 1, and 2, as randomized withdrawal. Below are some positive points learned from the company's conference call this morning. 

• File an NDA for fibromyalgia in the 2nd quarter
• A second GPO (group purchasing organization) has signed with Axsome
• 331 million in cash on hand, end of first quarter